Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Humanitarian Device Bill Would Gut Incentives For Pediatric Devices, AAP Says

This article was originally published in The Gray Sheet

Executive Summary

The American Academy of Pediatrics says a bill introduced in the House earlier this month intended to encourage more device makers to target rare diseases would undermine an effective incentive in place to spur development of devices for children.

You may also be interested in...



Negotiations Continue On Pediatric Device Reauthorization Provisions

Lawmakers in the House and Senate are still hammering out language to allow companies to continue to profit on humanitarian device exemptions with pediatric indications, and to reauthorize a grant program for non-profit pediatric device consortia.

Senate Draft Bill Compromises On Profit Incentive For Humanitarian Devices

More devices approved under a humanitarian device exemption could be priced for profit if draft Senate language is enacted, but restrictions are included to ensure that current pediatric incentives are not gutted.

Franken Bill Offers Retroactive Profit Incentive For Humanitarian Devices

A bill by Sens. Franken and Alexander to retroactively remove the profit restriction for all humanitarian-use devices is intended to give device firms more incentive to develop products for rare conditions, but an influential pediatric group says it will have unintended consequences.

Related Content

Topics

UsernamePublicRestriction

Register

MT030659

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel